Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Cyclophosphamide as Sole Graft-Versus-Host-Prophylaxis After Allogeneic Stem Cell Transplantation (OCTET-CY)

This study has been completed.
Information provided by (Responsible Party):
Christoph Scheid, University of Cologne Identifier:
First received: January 25, 2011
Last updated: June 8, 2014
Last verified: June 2014
A phase II clinical study to assess the efficacy of post-transplantation cyclophosphamide as single-agent GvHD prophylaxis after allogeneic hematopoietic stem cell transplantation in patients with multiple myeloma or lymphoma and to describe the influence of the modified immunosuppression concept on relapse rates, minimal residual disease, immune reconstitution and chimerism.

Condition Intervention Phase
Multiple Myeloma
Hodgkin's Disease
Drug: Cyclophosphamide
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: A Phase II Study to Investigate the Efficacy of Cyclophosphamide as Sole Graft-Versus-Host-Prophylaxis After Allogeneic Stem Cell Transplantation

Resource links provided by NLM:

Further study details as provided by University of Cologne:

Primary Outcome Measures:
  • Number of patients not requiring additional immunosuppression [ Time Frame: day 100 after transplant ]
    The primary endpoint is met if at least 1 of the 5 first patients and 3 of a total of 11 patient will reach day 100 after transplant without additional immunsuppressive drug treatment

Secondary Outcome Measures:
  • Overall Survival [ Time Frame: day 100 after transplant ]
  • engraftment [ Time Frame: day 100 after transplant ]
    absolute neutrophil count of > 0.5 x 10e9/l on 3 consecutive days

  • chimerism [ Time Frame: day 100 after transplant ]
    Percentage of donor cells in leukocytes from peripheral blood or bone marrow

  • relapse incidence [ Time Frame: day 100 after transplant ]
    cumulative incidence of relapse until day 100

  • acute GvHD [ Time Frame: day 100 after transplant ]
    cumulative incidence of acute GvHD

  • non-relapse mortality [ Time Frame: day 100 after transplant ]
    cumulative incidence of death from any cause without prior relapse or progression of malignant disease

  • immune reconstitution [ Time Frame: day 100 after transplant ]
    relative and absolute counts of B- and T-lymphocyte subsets in peripheral blood

Enrollment: 11
Study Start Date: March 2011
Study Completion Date: June 2014
Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: treatment arm
Drug: Cyclophosphamide
100 mg/kg total dose, infused on day +3 and +3 after allogeneic stem cell transplantation


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with multiple myeloma, Non-Hodgkin's lymphoma or Hodgkin's disease after allogeneic stem cell transplantation with reduced intensity conditioning

    • Written informed consent
    • No uncontrolled infections

Exclusion Criteria:

  • Severe organ dysfunction defined as:
  • Cardiac left ventricular ejection fraction (LVEF) of less than 35%
  • diffusing lung capacity (DLCO) of less than 40%
  • total lung capacity (TLC) of less than 40%
  • forced expiratory volume (FEV1) of less than 40%
  • total bilirubin >3mg/dl
  • creatinine-clearance of less than 40 ml/min
  • pregnancy or breast feeding
  • participation in other experimental drug trials
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01283776

University of Cologne
Cologne, Germany, 50924
Sponsors and Collaborators
University of Cologne
Principal Investigator: Christoph Scheid, MD PhD University of Cologne
  More Information

Responsible Party: Christoph Scheid, PD Dr. Christoph Scheid, University of Cologne Identifier: NCT01283776     History of Changes
Other Study ID Numbers: Uni-Koeln-1430
Study First Received: January 25, 2011
Last Updated: June 8, 2014

Additional relevant MeSH terms:
Multiple Myeloma
Lymphoma, Non-Hodgkin
Hodgkin Disease
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Lymphatic Diseases
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists processed this record on April 28, 2017